When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
GNMSF - J & J's Darzalex successful in late-stage study in first-line multiple myeloma
Genmab A/S Dkk
Genmab A/S (OTCPK:GNMSF) announces that a Phase 3 clinical trial, MAIA, evaluating licensee Janssen Biotech's (NYSE:JNJ) DARZALEX (daratumumab), combined with Celgene's (NASDAQ:CELG) REVLIMID (lenalidomide) and dexamethasone (DRd), compared to REVLIMID and dexamethasone alone (Rd) in newly diagnosed multiple myeloma patients who are not candidates for high-dose chemo and autologous stem cell transplant (ASCT) met the primary endpoint.
More news on: Genmab A/S, Johnson & Johnson, Celgene Corporation, Healthcare stocks news,